Actively Recruiting
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
Led by Zhejiang University · Updated on 2023-01-27
5000
Participants Needed
1
Research Sites
600 weeks
Total Duration
On this page
Sponsors
Z
Zhejiang University
Lead Sponsor
T
The Second Hospital of Hebei Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.
CONDITIONS
Official Title
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinically diagnosed with Intraductal Papillary Mucinous Neoplasm (IPMN)
- No other malignant tumors present
- Willing to sign informed consent
You will not qualify if you...
- Presence of mental disorders that affect cognition and cooperation
- Serious blood diseases or use of drugs affecting peripheral blood
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
T
Tingbo Liang, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here